Stock Market Reviews

Read and share opinions on MIST (Milestone Pharmaceuticals Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock

Latest News

• Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
  Nov 12, 2025
• Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Nov 4, 2025
• Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
  Nov 3, 2025
• Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
  Oct 9, 2025
• Milestone® Pharmaceuticals to Present at Upcoming Conferences
  Aug 19, 2025
• Milestone Pharmaceuticals: Q2 Earnings Snapshot
  Aug 12, 2025
• Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
  Aug 12, 2025
• Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
  Jul 11, 2025
• Milestone Pharmaceuticals Announces Proposed Public Offering
  Jul 11, 2025
• Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
  Jul 11, 2025
• Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
  Jun 16, 2025
• Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
  May 28, 2025
• Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
  May 22, 2025
• Milestone Pharmaceuticals: Q1 Earnings Snapshot
  May 14, 2025
• Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
  May 14, 2025
• Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen
  Apr 2, 2025
• TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty
  Apr 1, 2025
• Milestone CRL affirms integrity of clinical data, says H.C. Wainwright
  Mar 29, 2025
• FDA Issues Complete Response Letter for Etripamil for PSVT
  Mar 28, 2025